Neuraxis Inc (NRXS) Stock Analysis

AI analysis of Neuraxis Inc (NRXS)

Hold

Neuraxis Inc (NRXS) is currently priced at 6.60, which is near its 52-week low of 2.21 and significantly below its 52-week high of 9.33. The RSI is at 24.60, indicating the stock is oversold, which could suggest a potential rebound. However, the company has a forward P/E of 0 and has reported consistent net losses, with a net income of -2,277,249 in Q2 2026. The significant insider and hedge fund activity is neutral, indicating no strong buying or selling pressure from these groups. The main risk is the company's ongoing losses, as evidenced by a net margin of -108.14% in Q2 2026, which could hinder its ability to recover in the short term.

Valuation Metrics

The current forward P/E ratio for Neuraxis Inc (NRXS) is 0.00, compared to its 5-year average forward P/E of -17.02.

Forward P/E

Overvalued

5Y Average P/E

-17.02

Current P/E

0.00

Overvalued

-4.70

Undervalued

-29.35

Forward EV/EBITDA

Undervalued

5Y Average EV/EBITDA

-1.23

Current EV/EBITDA

-3.16

Overvalued

0.30

Undervalued

-2.76

Forward P/S

Fair

5Y Average P/S

2.88

Current P/S

3.88

Overvalued

4.42

Undervalued

1.33

Alphio AI Price Scenarios for NRXS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NRXS

$3.72

Scenario price

B

Base

Base · 50%NRXS

$2.45

Scenario price

B

Bear

Bear · 25%NRXS

$1.57

Scenario price

NRXS FAQ — answered by Alphio AI

Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Neuraxis Inc (NRXS) is currently priced at 6.60, which is near its 52-week low of 2.21 and significantly below its 52-week high of 9.33. The RSI is at 24.60, indicating the stock is oversold, which could suggest a potential rebound. However, the company has a forward P/E of 0 and has reported consistent net losses, with a net income of -2,277,249 in Q2 2026. The significant insider and hedge fund activity is neutral, indicating no strong buying or selling pressure from these groups. The main risk is the company's ongoing losses, as evidenced by a net margin of -108.14% in Q2 2026, which could hinder its ability to recover in the short term.